


BRACE CORONA

#ESCCongress



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with COVID-19 infection were randomized to temporary suspension of angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACEI/ARB) vs. continued use of ACEI/ARB.



RESULTS

- Primary outcome, number of days alive and out of the hospital through 30 days, was 21.9 in the suspension of ACEI/ARB group compared with 22.9 in the continuation of ACEI/ARB group (p = 0.09)

CONCLUSIONS

- Among patients hospitalized with COVID-19 infection and receiving chronic ACEI/ARB, suspending these medications compared with continuing them did not improve the days alive and out of the hospital

Presented by Dr. Renato D. Lopes at ESC Virtual Congress 2020